261 related articles for article (PubMed ID: 16949200)
1. Phosphodiesterase type 5 inhibitors: the day after.
Hatzimouratidis K; Hatzichristou D
Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
3. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
[TBL] [Abstract][Full Text] [Related]
4. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
5. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
[TBL] [Abstract][Full Text] [Related]
6. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
7. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
9. [Update of PDE5 inhibitors as treatment of ED].
Lu YN; Chen B
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
[TBL] [Abstract][Full Text] [Related]
10. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase inhibitors in Raynaud's phenomenon.
Levien TL
Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
[TBL] [Abstract][Full Text] [Related]
12. Pills for erectile dysfunction: now there are three.
Harv Mens Health Watch; 2004 Apr; 8(9):5-6. PubMed ID: 15100064
[No Abstract] [Full Text] [Related]
13. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
[TBL] [Abstract][Full Text] [Related]
14. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 inhibitors: current status and potential applications.
Rotella DP
Nat Rev Drug Discov; 2002 Sep; 1(9):674-82. PubMed ID: 12209148
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
20. Visual loss with erectile dysfunction medications.
Wooltorton E
CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
